Crossmark

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Published Online: 2024-03-01

Authors

Smoots, Stephen G.

Schreiber, Anna R.

Jackson, Marilyn M.

Bagby, Stacey M.

Dominguez, Adrian T A.

Dus, Evan D.

Binns, Cameron A.

MacBeth, Morgan

Whitty, Phaedra A.

Diamond, Jennifer R.

Pitts, Todd M.
Funding

Funding for this research was provided by:

National Institutes of Health (5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25, 5P30CA046934-25)
License Information

Text and Data Mining valid from 2024-03-01

Version of Record valid from 2024-03-01
More Information

Article History

Received: 8 November 2023

Accepted: 27 February 2024

First Online: 1 March 2024

Declarations

:

: All murine studies were performed following the approval of University of Colorado Anschutz Medical Campus Institutional Animal Care and Use Committee.

: Not applicable

: JRD has stock options for OnKure, Inc. and is a paid consultant for OnKure, Inc. TMP had research support from OnKure, Inc.

: Not applicable.

Document is current